0001628280-16-021527.txt : 20161223 0001628280-16-021527.hdr.sgml : 20161223 20161117133335 ACCESSION NUMBER: 0001628280-16-021527 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 750 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 750 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 CORRESP 1 filename1.htm Document


ADAMAS PHARMACEUTICALS, INC.
1900 Powell Street, Suite 750
Emeryville, CA 94608
(510) 450-3500


November 16, 2016
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Suzanne Hayes
RE:
Adamas Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-214409
Ladies and Gentlemen:
Adamas Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on November 21, 2016, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Very truly yours,
Adamas Pharmaceuticals, Inc.

By:     /s/ William J. Dawson        
William J. Dawson
Chief Financial Officer